INBX
Inhibrx Biosciences, Inc.
$101.32
-9.25
(-8.37%)
Mkt Cap
1.49B
Volume
552,828
52W Range
12.675-155.29
Sector
Healthcare
Beta
3.89
EPS (TTM)
-8.39
P/E Ratio
-8.74
Revenue (TTM)
1.30M
Rev Growth (5Y)
-36.7%
EPS Growth (5Y)
N/A
Company Description
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.30M | 200,000 | 1.80M | 2.19M | 7.12M | 12.81M | 9.09M | 7.50M | 7.95M | 6.67M |
| Net Income | (140.06M) | 1.69B | (241.36M) | (145.23M) | (81.77M) | (75.64M) | (51.40M) | (31.16M) | (19.44M) | (8.27M) |
| EPS | -9.04 | 116.58 | -5.12 | -3.62 | -2.15 | -2.99 | -1.41 | -1.15 | -0.68 | -0.23 |
| Free Cash Flow | (129.82M) | (197.01M) | (197.90M) | (115.99M) | (81.19M) | (49.33M) | (33.89M) | (24.52M) | (20.09M) | (18.32M) |
| FCF / Share | -8.38 | -13.61 | -4.20 | -2.89 | -2.14 | -1.95 | -0.93 | -0.91 | -0.70 | -0.50 |
| Operating CF | (129.79M) | (194.41M) | (193.31M) | (115.30M) | (80.32M) | (47.97M) | (32.08M) | (23.09M) | (18.75M) | (18.11M) |
| Total Assets | 146.48M | 180.77M | 307.89M | 290.88M | 150.45M | 143.74M | 26.49M | 9.98M | 17.25M | 21.27M |
| Total Debt | 107.01M | 8.05M | 210.14M | 207.10M | 72.14M | 37.45M | 41.73M | 9.49M | 14.66M | 18.92M |
| Cash & Equiv | 124.22M | 152.60M | 277.92M | 273.87M | 131.30M | 128.66M | 11.54M | 2.10M | 13.47M | 20.02M |
| Book Value | 7.99M | 133.58M | 43.50M | 58.06M | 52.38M | 75.47M | (93.57M) | (57.64M) | (28.77M) | (9.25M) |
| Return on Equity | -17.52 | 12.63 | -5.55 | -2.50 | -1.56 | -1.00 | N/A | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1.30M | 0 | 100,000 | 0 | 100,000 | 0 | 1.63M | 119,000 | 30,000 |
| Net Income | (33.44M) | (32.83M) | (35.26M) | (28.65M) | (43.31M) | (47.87M) | (43.86M) | 1.86B | (78.71M) | (93.60M) | (51.79M) | (47.05M) |
| EPS | -2.15 | -2.11 | -2.28 | -1.85 | -2.80 | -3.31 | -2.84 | 128.35 | -1.44 | -1.73 | -1.10 | -1.08 |
| Free Cash Flow | (38.03M) | (30.12M) | (33.83M) | (29.95M) | (35.92M) | (43.74M) | (30.53M) | (58.57M) | (64.17M) | (60.26M) | (55.06M) | (42.62M) |
| FCF / Share | -2.44 | -1.94 | -2.19 | -1.94 | -2.32 | -3.02 | -1.97 | -4.05 | -1.18 | -1.12 | -1.17 | -0.98 |
| Operating CF | (38.03M) | (30.12M) | (33.82M) | (29.95M) | (35.90M) | (43.72M) | (30.28M) | (57.36M) | (63.05M) | (56.82M) | (54.24M) | (42.30M) |
| Total Assets | 183.97M | 146.48M | 177.47M | 212.12M | 242.64M | 180.77M | 222.56M | 258.42M | 288.58M | 307.89M | 372.73M | 213.17M |
| Total Debt | 5.90M | 107.01M | 6.99M | 106.79M | 106.53M | 8.05M | 1.83M | 2.17M | 210.89M | 210.14M | 207.37M | 208.61M |
| Cash & Equiv | 161.66M | 124.22M | 153.09M | 186.57M | 216.52M | 152.60M | 196.33M | 226.86M | 252.48M | 277.92M | 337.33M | 192.49M |
| Book Value | (21.04M) | 7.99M | 36.83M | 68.56M | 94.44M | 133.58M | 178.47M | 219.37M | 11.57M | 43.50M | 129.59M | (24.81M) |
| Return on Equity | N/A | -4.11 | -0.96 | -0.42 | -0.46 | -0.36 | -0.25 | 8.47 | -6.80 | -2.15 | -0.40 | N/A |
INBX News
Inhibrx Reports First Quarter 2026 Financial Results
Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study
Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer